Press Releases Press Releases Year: - Any -2019201820172016201520142013 October 31, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Summary ToggleMelinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP October 26, 2018 Summary ToggleMelinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 October 22, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer October 05, 2018 Summary ToggleMelinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program October 02, 2018 Summary ToggleMelinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam) October 01, 2018 Summary ToggleMelinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries September 25, 2018 Summary ToggleMelinta Therapeutics to Present at Upcoming Investor Conferences September 24, 2018 Summary ToggleMelinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018 September 21, 2018 Summary ToggleMelinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
Press Releases Year: - Any -2019201820172016201520142013 October 31, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Summary ToggleMelinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP October 26, 2018 Summary ToggleMelinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 October 22, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer October 05, 2018 Summary ToggleMelinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program October 02, 2018 Summary ToggleMelinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam) October 01, 2018 Summary ToggleMelinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries September 25, 2018 Summary ToggleMelinta Therapeutics to Present at Upcoming Investor Conferences September 24, 2018 Summary ToggleMelinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018 September 21, 2018 Summary ToggleMelinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
